Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Advances in Personalized Treatment of Breast Cancer
share announcement

Advances in Personalized Treatment of Breast Cancer

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 10 September 2024 | Viewed by 3857

Special Issue Editor

Dr. Gianluca Franceschini

E-Mail Website1 Website2
Guest Editor
Breast Unit, Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica, Rome, Italy
Interests: breast cancer treatment; oncoplastic surgery; breast surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Breast cancer is commonly considered an international health priority; it is the most common tumour in women in the world, and epidemiological data show a progressive increase in its incidence.

The evolution of evidence-based guidelines in important disciplines such as surgery, radiotherapy, and medical oncology is leading to a steady improvement in survival rates.

In recent years, the management of breast cancer has progressively evolved towards less aggressive approaches with the adoption of new therapeutic strategies based on integrated and precision oncology.

Today, treatments are personalized for each patient and based on individual peculiarities (age, associated pathologies, presence of genetic mutations) and on the characteristics of the disease (staging, biological, molecular, and genomic profiles).

This Special Issue will highlight the recent advances in personalized breast cancer treatment, their potential benefits, and the many open questions that have yet to be properly defined and answered.

We invite the submission of the following types of manuscripts: original research articles; meta-analyses; systematic reviews; review articles; method articles; perspective articles; and technology reports.

Dr. Gianluca Franceschini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer treatment
  • oncoplastic surgery
  • conservative mastectomy
  • breast reconstruction
  • sentinel node biopsy
  • chemotherapy
  • radiotherapy
  • integrated therapies
  • precision medicine
  • personalized treatment

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1600 KiB  
Article
Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital
by Inbal Dona Amar, Gianluca Franceschini, Camilla Nero, Ilaria Pasqua, Ida Paris, Armando Orlandi, Stefania Gori, Alessandra Fabi, Giorgia Garganese, Giovanni Scambia and Paola Villa
J. Pers. Med. 2024, 14(4), 371; https://doi.org/10.3390/jpm14040371 - 30 Mar 2024
Viewed by 710
Abstract
Background: We assess the impact of bone health clinical management in breast cancer (BC) patients receiving adjuvant endocrine therapy and design a personalized clinical pathway to reduce bone loss in an Italian research hospital. Methods: The primary endpoint was to assess (through the [...] Read more.
Background: We assess the impact of bone health clinical management in breast cancer (BC) patients receiving adjuvant endocrine therapy and design a personalized clinical pathway to reduce bone loss in an Italian research hospital. Methods: The primary endpoint was to assess (through the process improvement organizational method) the clinical pathway that post-surgical BC patients prescribed with endocrine therapy undergo to prevent bone loss. The secondary endpoint was to design a personalized clinical pathway for a prompt implementation of guidelines, to assess and possibly prescribe antiresorptive therapy. Results: During the first year of the execution of the new Diagnostic Therapeutic Assistance Pathway, a 60% increase in Dual-Energy X-ray Absorptiometry evaluations within 30 days and a 39.5% increase in antiresorptive therapy prescription within 90 days (since the prescription of endocrine therapy) were shown, thus increasing patients’ compliance. Conclusion: Case managers and bone health specialists in this context can improve patients’ adherence to therapies and bone health, helping physicians to expand their collaboration. Full article
(This article belongs to the Special Issue Advances in Personalized Treatment of Breast Cancer)
►▼ Show Figures

Graphical abstract

12 pages, 560 KiB  
Article
Exome Sequencing Reveals Novel Germline Variants in Breast Cancer Patients in the Southernmost Region of Thailand
by Panupong Sukpan, Surasak Sangkhathat, Hutcha Sriplung, Wison Laochareonsuk, Pongsakorn Choochuen, Nasuha Auseng, Weerawan Khoonjan, Rusta Salaeh, Kornchanok Thangnaphadol, Kasemsun Wanawanakorn and Kanyanatt Kanokwiroon
J. Pers. Med. 2023, 13(11), 1587; https://doi.org/10.3390/jpm13111587 - 9 Nov 2023
Viewed by 1465
Abstract
Germline carriers of pathogenic variants in cancer susceptibility genes are at an increased risk of breast cancer (BC). We characterized germline variants in a cohort of 151 patients diagnosed with epithelial BC in the southernmost region of Thailand, where the predominant ethnicity differs [...] Read more.
Germline carriers of pathogenic variants in cancer susceptibility genes are at an increased risk of breast cancer (BC). We characterized germline variants in a cohort of 151 patients diagnosed with epithelial BC in the southernmost region of Thailand, where the predominant ethnicity differs from that of the rest of the country. Whole exome sequencing was used to identify and subsequently filter variants present in 26 genes known to be associated with cancer predisposition. Of the 151 individuals assessed, 23, corresponding to 15.2% of the sample, exhibited the presence of one or more pathogenic or likely pathogenic variants associated with BC susceptibility. We identified novel germline truncating variants in BRIP1, CHEK2, MSH6, PALB2, and PTEN and annotated variants of uncertain significance (VUSs), both novel and previously documented. Therefore, it is advisable to use genetic testing as an additional risk screening method for BC in this area. Full article
(This article belongs to the Special Issue Advances in Personalized Treatment of Breast Cancer)
►▼ Show Figures

Figure 1

18 pages, 2766 KiB  
Article
Breast Cancer Tissue Explants: An Approach to Develop Personalized Therapy in Public Health Services
by Pilar Carranza-Rosales, Daniel Valencia-Mercado, Olga Esquivel-Hernández, Manuel Ismael González-Geroniz, José Inocente Bañuelos-García, Ana Lilia Castruita-Ávila, Mario Alberto Sánchez-Prieto, Ezequiel Viveros-Valdez, Javier Morán-Martínez, Isaías Balderas-Rentería, Nancy Elena Guzmán-Delgado and Irma Edith Carranza-Torres
J. Pers. Med. 2023, 13(10), 1521; https://doi.org/10.3390/jpm13101521 - 23 Oct 2023
Viewed by 1413
Abstract
Breast cancer is one of the main causes of death worldwide. Lately, there is great interest in developing methods that assess individual sensitivity and/or resistance of tumors to antineoplastics to provide personalized therapy for patients. In this study we used organotypic culture of [...] Read more.
Breast cancer is one of the main causes of death worldwide. Lately, there is great interest in developing methods that assess individual sensitivity and/or resistance of tumors to antineoplastics to provide personalized therapy for patients. In this study we used organotypic culture of human breast tumor slices to predict the experimental effect of antineoplastics on the viability of tumoral tissue. Samples of breast tumor were taken from 27 patients with clinically advanced breast cancer; slices were obtained and incubated separately for 48 h with paclitaxel, docetaxel, epirubicin, 5-fluorouracil, cyclophosphamide, and cell culture media (control). We determined an experimental tumor sensitivity/resistance (S/R) profile by evaluating tissue viability using the Alamar Blue® metabolic test, and by structural viability (histopathological analyses, necrosis, and inflammation). These parameters were related to immunohistochemical expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. The predominant histological type found was infiltrating ductal carcinoma (85.2%), followed by lobular carcinoma (7.4%) and mixed carcinoma (7.4%). Experimental drug resistance was related to positive hormone receptor status in 83% of samples treated with cyclophosphamide (p = 0.027). Results suggest that the tumor S/R profile can help to predict personalized therapy or optimize chemotherapeutic treatments in breast cancer. Full article
(This article belongs to the Special Issue Advances in Personalized Treatment of Breast Cancer)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop